Literature DB >> 20567962

[Course modifying therapy of Alzheimer's dementia].

M T Heneka1.   

Abstract

The current therapy of Alzheimer's disease is primarily symptomatic. Drugs which aim to modify the course of the disease are currently being developed and tested in clinical trials. Given the complex and partly unknown pathogenesis of the disease, failure of such forms of therapy has to be taken into account. Clinical epidemiology suggests a possible neuroprotective effect of statins and non-steroidal anti-inflammatory drugs, however, the molecular basis of these effects has to be further unraveled. Therapies that modify the course of Alzheimer's disease are only likely to be effective years if not decades before the disease becomes clinically apparent. Thus, the therapy of risk factors including arterial hypertension and obesity in midlife as well as a Mediterranean diet currently provides the highest chance of modifying the course of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567962     DOI: 10.1007/s00115-010-3000-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  30 in total

Review 1.  Exercise your amyloid.

Authors:  Stanislav L Karsten; Daniel H Geschwind
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

Review 2.  The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors.

Authors:  Paul S Aisen
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease.

Authors:  Miia Kivipelto; Tiia Ngandu; Laura Fratiglioni; Matti Viitanen; Ingemar Kåreholt; Bengt Winblad; Eeva-Liisa Helkala; Jaakko Tuomilehto; Hilkka Soininen; Aulikki Nissinen
Journal:  Arch Neurol       Date:  2005-10

Review 4.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

6.  Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.

Authors:  S Gauthier; P S Aisen; S H Ferris; D Saumier; A Duong; D Haine; D Garceau; J Suhy; J Oh; W Lau; J Sampalis
Journal:  J Nutr Health Aging       Date:  2009-06       Impact factor: 4.075

7.  Mediterranean diet and mild cognitive impairment.

Authors:  Nikolaos Scarmeas; Yaakov Stern; Richard Mayeux; Jennifer J Manly; Nicole Schupf; Jose A Luchsinger
Journal:  Arch Neurol       Date:  2009-02

8.  Diet-induced insulin resistance impairs hippocampal synaptic plasticity and cognition in middle-aged rats.

Authors:  Alexis M Stranahan; Eric D Norman; Kim Lee; Roy G Cutler; Richard S Telljohann; Josephine M Egan; Mark P Mattson
Journal:  Hippocampus       Date:  2008       Impact factor: 3.899

Review 9.  Gamma-secretase inhibition and modulation for Alzheimer's disease.

Authors:  Michael S Wolfe
Journal:  Curr Alzheimer Res       Date:  2008-04       Impact factor: 3.498

Review 10.  Natural human antibodies to amyloid beta peptide.

Authors:  Paul Szabo; Norman Relkin; Marc E Weksler
Journal:  Autoimmun Rev       Date:  2008-04-10       Impact factor: 9.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.